Skip to content
Screener

AnaptysBio, Inc. ANAB Other operating expenses

Other operating expenses at other companies

Biogen logo
BiogenBIIB
-$18.5M+62.0%
Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
$47M+36.9%
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
$66.83M+0.2%
Absci Corporation logo
Absci CorporationABSI
$31.06M+7.4%
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
$82.77M+31.2%
Upstream Bio, Inc. logo
Upstream Bio, Inc.UPB
$44.65M+37.0%

Other financials

Income statement

See full
Revenue$25.6M-8.0%
Operating income-$34.6M-25.8%
Net income-$52.9M-34.5%
EPS (diluted)-$1.84-43.8%

Balance sheet

See full
Cash & equivalents$248.5M+152%
Total debt$13.6K-99.9%
Total equity$12.7M-62.5%
Total assets$329.7M-21.9%

Cash flow

See full
Operating cash flow-$25.9M-142%
CapEx$17.0K-51.4%
Free cash flow-$25.9M-142%

Valuation

See full
Market cap$1.62B+145%
Enterprise value$1.37B+117%
P/S+1.6×

Profitability

See full
Operating margin17.6%+9.6pp
Net margin-49.9%-22.6pp
FCF margin1.9%+1.0pp

Returns & leverage

See full
Return on equity-343.8%-1,012pp
Debt / equity-0.5×
Current ratio7.6×-0.7×

Where this comes from

Reported directly by AnaptysBio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingExpenses.

The source filing: AnaptysBio, Inc.’s 10-Q, filed May 12, 2026.

Filed
May 12, 2026, 4:20 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-219515
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Operating expenses:
Research and development33,99141,180
General and administrative26,20214,130
Total operating expenses60,19355,310
Loss from operations(34,637)(27,539)
Other income (expense), net:
Interest income2,6534,413
Non-cash interest expense for the sale of future royalties(20,859)(18,061)

Item 1. Consolidated Financial Statements

FAQ

What is AnaptysBio, Inc.'s other operating expenses?
AnaptysBio, Inc. (ANAB) reported other operating expenses of $60.19M in Q1 2026.
How has AnaptysBio, Inc.'s other operating expenses changed year-over-year?
AnaptysBio, Inc.'s other operating expenses increased by 8.8% year-over-year, from $55.31M to $60.19M.
What is the long-term trend for AnaptysBio, Inc.'s other operating expenses?
Over 4 years (2021 to 2025), AnaptysBio, Inc.'s other operating expenses has grown at a 11.7% compound annual growth rate (CAGR), from $119.99M to $186.71M.
What does other operating expenses mean?
Residual operating expenses not classified into specific categories, serving as a catch-all for miscellaneous operating costs.

Ask your AI about AnaptysBio, Inc.'s other operating expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude